February FDA NDA/BLA Approvals

2/01 Cosopt PF, Merck Sharp Dohme; 2/03 Giazo, Salix Pharmaceuticals ; 2/07 Mitosol, Mobius Therapeutics;
2/07 Sklice, Sanofi-Topaz; 2/10 Zioptan, Merck Sharp Dohme



Top 15 Potential Blockbusters in Development
There is a feeling in the industry that the day of the multi-billion dollar drug is over. That the market is transitioning to more specialized and targeted therapies. However, according to John Carroll, Editor-in-Chief at Fierce-Biotech, “Despite rumors to the contrary, the blockbuster is far from dead. Here are 15 hopefuls that are alive and kicking.”

  1. The drug: T-DM1
    The disease: Breast cancer
    The developers: Roche/Genentech, ImmunoGen
    Peak sales potential: $5 billion-plus
  2. The drug: BG-12
    The disease: Multiple sclerosis
    The developer: Biogen Idec
    Peak sales potential: $3 billion or so
  3. The drug: Darapladib
    The disease: Atherosclerosis
    The developer: GlaxoSmithKline
    Peak sales potential: Multibillion-dollar market
  4. The drug: Gantenerumab
    The disease: Alzheimer's
    The developers: Roche, MorphoSys AG Peak sales potential: The sky's the limit.
  5. The drug: GS-7977
    The disease: Hepatitis C
    The developer: Gilead
    Peak sales potential: Barclays analyst Tony Butler says $3.8 billion
  6. The drug: REGN727
    The disease: Cardiovascular disease
    The developers: Sanofi/Regeneron
    Peak sales potential: Some estimates start at $2.5 billion, though Deutsche Bank analyst Robyn Karnauskas leads the cheering section with $3 billion to $6 billion in potential.
  7. The drug: Odanacatib
    The disease: Osteoporosis
    The developer: Merck
    Peak sales potential: $2.5 billion (Barclays)
  8. The drug: Anacetrapib
    The disease: Cardiovascular
    The developer: Merck
    Peak sales potential: Estimates range anywhere from $3 billion to $10 billion, but skepticism about its ultimate success seems to be growing.
  9. The drug: Eliquis (apixaban)
    The disease: Atrial fibrillation
    The developer: Bristol-Myers Squibb, Pfizer
    Peak sales potential: Estimates start around $3.8 billion and rise to $5 billion or more.
  10. The drug: Tofacitinib
    The disease: Rheumatoid arthritis
    The developer: Pfizer
    Peak sales potential: $2 billion to $3 billion
  11. The drug: Bardoxolone
    The disease: Chronic kidney disease
    The developers: Reata, Abbott (AbbVie)
    Peak sales potential: Reata believes this drug will earn billions.
  12. The drug: Lu AA21004
    The disease: Major depression
    The developers: Lundbeck, Takeda
    Peak sales potential: Lundbeck estimates $2 billion, and they need it.
  13. The drug: QVA149
    The disease: COPD
    The developers: Novartis, Vectura
    Peak sales potential: Analysts at Credit Suisse have assigned a 50% probability of success with $750 million peak sales for QVA149 ex-U.S. and a 40% shot at $750 million in the U.S.
  14. The drug: Macitentan
    The disease: Pulmonary arterial hypertension
    The developer: Actelion
    Peak sales potential: $1.4 billion to $3 billion
  15. The drug: Alpharadin
    The disease: Cancer
    The developers: Bayer, Algeta
    Peak sales potential: $1 billion-plus Full Story at: FierceBiotech


We have compiled a few links to some sites that we’ve found valuable for our business that we’d like to share:


“My goal is to match qualified and dedicated candidates with stimulating client companies, which will result in a better lifestyle and work environment for all. I look to partner with individuals who have a passion for what they do professionally and personally. Most importantly, I am myself and I expect the same honesty and integrity I provide.”

Before starting in the business of recruiting, I graduated from University of California, San Diego. After which, I worked in cancer research for three years. This knowledge base in science has given me a unique understanding and appreciation for life sciences. I have been with MR Vancouver since 2000 working in the life science industry. I am a Certified Senior Account Manager through MRINetwork, allowing me to continue to sharpen my skills in the recruitment industry and was the Regional CSAM of the Year for 2010.

Industries Served

  • Biotechnology
  • Device
  • Diagnostic
  • Pharmaceutical

Current Openings

  • Here are examples of current openings:
  • Senior Director Market Access
  • Senior Director Market Research
  • Director Scientific Strategy
  • Associate Director NPP Market Research
  • Senior Manager MHC Market Research
  • Manager Contract Analysis
  • Product Manager
  • Manager Commercial Reporting
  • Senior Analyst Commercial Contracts

Contact Me
Michelle’s LinkedIn Profile
700 Washington St Suite 508
Vancouver, WA 98660
T 877.695.4688 | F 360.695.4384

First Friday

Searching for Perfect Candidate
May Miss the Perfect Match

When hiring managers begin to write the list of qualifications, they build lists of everything they think they want in a candidate. It's a process not unlike building a dating profile; pulling characteristics out of the air to describe the perfect match. In dating, people tend to understand that finding someone who matches that description is unlikely. When they find someone they like, it is almost a coincidence when they match even the broadest elements of the original profile.

By contrast, hiring managers frequently use far less latitude in their candidate searches. The descriptions involve far more precise requirements and they are less likely to waiver on them should someone outside of the criteria apply.

"Using vetting of candidates based on stringent requirements can keep out the candidates who have no place in an organization, but there isn’t an automated filter that is going to increase your ability to identify, much less attract impact players to your organization," says Rob Romaine, president of MRINetwork. "There isn't an accredited Master of Innovative Thinking degree or Doctorate of Self Starting, and a resume that claims someone has such qualities only means they know those skills are important."
The 8.2 percent national unemployment rate, and even the 3.9 percent bachelor's degree and higher unemployment rate, seem to still give employers a false sense of plentiful candidate supply. It's like the man stranded on a tropical island, surrounded by salt water — yet dying of thirst.
"In the early days of the recession, we saw amazing candidate availability. Top candidates truly were victims of circumstance — doing great work but losing their positions regardless — and became available on the active candidate market," notes Romaine. "But a type of reverse osmosis has had time to set in. The most desirable candidates found new positions. Today's unemployed population — especially the professional space — largely consists of people whose skills and education doesn’t match with the needs of the marketplace.
More than 22 percent of the U.S. workforce is in a professional or related occupation, but less than 11 percent of the 12.2 million people unemployed in May have professional experience. That translates to just 1.3 million lawyers, engineers, economists, computer programmers and more who are unemployed today and actively looking for a job. If you widen the net to include managers and financial professionals, the statistic grows to 38 percent of the U.S. workforce but still less than 19 percent of the unemployed population.
"When talking casually to hiring managers they know how tight the market is, they understand that of the 1.3 million professionals who are unemployed, they are unlikely to find that one person with fifteen years of wind propulsion experience who is willing to relocate to them," says Romaine. "But as soon hiring a candidate leaves the abstract and interviews are being conducted, managers start looking at the 8.2 percent unemployment rate or the 17.9 underemployment rate and hold out for a candidate who matches the detailed profile they’ve written. By holding the line so tightly, though, they will often overlook someone who could actually be their perfect match."

July 2012 | Issue 7 | Vol. VI

Management Recruiters of Vancouver, LLC
700 Washington St, Suite 508
Vancouver, WA 98660

The trends in the employment data aren't surprising to Jack Downing, a managing partner with the job placement firm MRINetwork WorldBridge Partners.
In the past six months or so, Downing said he's started to see such high demand for college graduates, particularly in fields such as engineering and information technology, that some candidates are fielding multiple job offers.
Jack Downing, WorldBridge Partners - Chicago
As quoted on, June 4, 2012

French unemployment reached 10 percent in April, its highest point since late 1999. Socialist President Francois Hollande replaced Nicolas Sarkozy on May 15, and has been tasked with righting Europe's second largest economy. Via Reuters.
In China, college graduates are expected to be entering one of the toughest labor markets in recent memory just as graduation rates in the country begin to explode. Between 2008 and 2011, the number of newly minted college graduates grew from 5.6 to 7.7 million. State media points out, however, that college enrollment ratios are still far lower than in many western countries. Via China Daily.

BLS Employment Situation Report: May 2012
Total employment in the U.S. grew by 69,000 positions in May and unemployment grew for the first time in more than a year from 8.1 to 8.2 percent as nearly half a million high school and college graduates entered the workforce.
Japanese culture plays major role in hiring process
Expert: Hiring process must be thorough
Obama administration seeks to increase hiring